Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Year: 2021
Type: article
Abstract: Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
Source: Blood Cancer Journal
Authors: Carlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, Bruno Paiva, Monika Engelhardt, Saad Usmani, Jo Caers, Wilson Gonsalves, Fredrik Schjesvold, Giampaolo Merlini, Suzanne Lentzch, Enrique Ocio, Laurent Garderet, Philippe Moreau, Pieter Sonneveld, Ashraf Badros, Gösta Gahrton, Hartmut Goldschmidt, Sascha Tuchman, Hermann Einsele, Brian Durie, Baldeep Wirk, Pellegrino Musto, Patrick Hayden, Martin Kaiser, Jesús San Miguel, Joan Bladé, S. Vincent Rajkumar, Maria Victoria Mateos
Institutions: Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Mayo Clinic, Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, University of Freiburg, University Medical Center Freiburg, Levine Cancer Institute, Centre Hospitalier Universitaire de Liège, Oslo University Hospital, University of Pavia, Columbia University, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Hôpital Saint-Antoine, Centre Hospitalier Universitaire de Nantes, Erasmus MC, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Karolinska Institutet, University Hospital Heidelberg, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Würzburg, Universitätsklinikum Würzburg, Cedars-Sinai Medical Center, Penn State Cancer Institute, Centro di Riferimento Oncologico della Basilicata, St. James's Hospital, Institute of Cancer Research
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,480
Funders: Amgen, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, Johns Hopkins University, Regeneron Pharmaceuticals, Incyte, SkylineDx, Generalitat de Catalunya, Merck Sharp and Dohme, Chugai Pharmaceutical, Sanofi Genzyme, Pharmacyclics, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, European Regional Development Fund
OpenAlex ID: W3217094546